Literature DB >> 31195137

Alteration of the Intestinal Microbiota by Broad-Spectrum Antibiotic Use Correlates with the Occurrence of Intestinal Graft-versus-Host Disease.

Sung-Eun Lee1, Ji-Young Lim1, Da-Bin Ryu1, Tae Woo Kim1, Sung Soo Park1, Young-Woo Jeon1, Jae-Ho Yoon1, Byung-Sik Cho1, Ki-Seong Eom1, Yoo-Jin Kim1, Hee-Je Kim1, Seok Lee1, Seok-Goo Cho1, Dong-Wook Kim1, Jong Wook Lee1, Chong-Su Kim2, Dong-Mi Shin3, Chang-Ki Min4.   

Abstract

Patients undergoing hematopoietic stem cell transplantation (HSCT) frequently receive empiric antibiotics during the neutropenic period before engraftment. Several recent studies have shown that anaerobes in the intestine are important mediators of intestinal homeostasis, and that commensal bacteria can be potent modulators of the severity of acute graft-versus-host disease (aGVHD). However, the relationships among the type of antibiotic used during the neutropenic period, changes in the intestinal microbiota, and subsequent occurrence of aGVHD are not clear. In this study, a total of 211 patients undergoing HSCT were stratified into 3 groups: patients not treated with any antibiotics during the neutropenic period (group 1; n = 43), patients treated with cefepime only (group 2; n = 87), and patients treated with carbapenem antibiotics, defined as meropenem or prepenem with or without previous cefepime therapy (group 3; n = 81). Intestinal microbiota analyses were performed on pre- and post-HSCT stool samples, and immunophenotypic analyses were performed on pre- and post-HSCT peripheral blood samples. Among the 211 patients, 95 (45%) developed aGVHD (grade ≥II), including 54 with intestinal GVHD. The incidence of intestinal GVHD was higher in group 3 compared with group 1 and group 2 (32.1%, 11.6%, and 26.4%, respectively; P = .044). After adjusting for potentially significant variables identified by univariate analysis, multivariate analyses identified broad-spectrum antibiotic use during the neutropenic period as associated with the occurrence of intestinal GVHD (hazard ratio, 3.25; 95% confidence interval, 1.13 to 9.34; P = .029). Accordingly, loss of bacterial diversity in terms of alterations in intestinal microbiota after HSCT was observed in patients who received broad-spectrum antibiotics. Moreover, alterations in the frequencies of several intestinal bacteria phyla were associated with the occurrence of intestinal GVHD. Evaluation of circulating immune cell subsets according to type of antibiotic used during the neutropenic period revealed delayed recovery of myeloid-derived suppressor cells in the broad-spectrum antibiotic use group. Our data indicate that the use of broad-spectrum antibiotics during the neutropenic period is associated with a higher incidence of intestinal GVHD via loss of microbiome diversity. Further studies are needed to determine whether maintaining bacterial diversity can help prevent the development of aGVHD.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute graft-versus-host disease; Antibiotics; Intestinal graft-versus-host disease; Intestinal tract microbiome diversity

Mesh:

Substances:

Year:  2019        PMID: 31195137     DOI: 10.1016/j.bbmt.2019.06.001

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  Anaerobic Antibiotics and the Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  John S Tanaka; Rebecca R Young; Sarah M Heston; Kirsten Jenkins; Lisa P Spees; Anthony D Sung; Kelly Corbet; Jillian C Thompson; Lauren Bohannon; Paul L Martin; Andre Stokhuyzen; Richard Vinesett; Doyle V Ward; Shakti K Bhattarai; Vanni Bucci; Mehreen Arshad; Patrick C Seed; Matthew S Kelly
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-17       Impact factor: 5.742

2.  Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease.

Authors:  Eiko Hayase; Tomo Hayase; Mohamed A Jamal; Takahiko Miyama; Chia-Chi Chang; Miriam R Ortega; Saira S Ahmed; Jennifer L Karmouch; Christopher A Sanchez; Alexandria N Brown; Rawan K El-Himri; Ivonne I Flores; Lauren K McDaniel; Dung Pham; Taylor Halsey; Annette C Frenk; Valerie A Chapa; Brooke E Heckel; Yimei Jin; Wen-Bin Tsai; Rishika Prasad; Lin Tan; Lucas Veillon; Nadim J Ajami; Jennifer A Wargo; Jessica Galloway-Peña; Samuel Shelburne; Roy F Chemaly; Lauren Davey; Robert W P Glowacki; Chen Liu; Gabriela Rondon; Amin M Alousi; Jeffrey J Molldrem; Richard E Champlin; Elizabeth J Shpall; Raphael H Valdivia; Eric C Martens; Philip L Lorenzi; Robert R Jenq
Journal:  Cell       Date:  2022-09-29       Impact factor: 66.850

3.  Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease

Authors:  Caitlin W Elgarten; Yimei Li; Kelly D Getz; Michael Hemmer; Yuan-Shung V Huang; Matthew Hall; Tao Wang; Carrie L Kitko; Madan H Jagasia; Taiga Nishihori; Hemant S Murthy; Hasan Hashem; Mitchell S Cairo; Akshay Sharma; Shahrukh K Hashmi; Medhat Askar; Amer Beitinjaneh; Matthew S Kelly; Jeffery J Auletta; Sherif M Badawy; Melissa Mavers; Richard Aplenc; Margaret L MacMillan; Stephen R Spellman; Mukta Arora; Brian T Fisher
Journal:  Transplant Cell Ther       Date:  2020-12-21

Review 4.  Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Maud D'Aveni; Anne B Notarantonio; Allan Bertrand; Laura Boulangé; Cécile Pochon; Marie T Rubio
Journal:  Front Immunol       Date:  2020-05-22       Impact factor: 7.561

5.  A gut microbiota score predicting acute graft-versus-host disease following myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Lijie Han; Ke Zhao; Yuanyuan Li; Haohao Han; Lizhi Zhou; Ping Ma; Zhiping Fan; Hui Sun; Hua Jin; Zhongxing Jiang; Qifa Liu; Jie Peng
Journal:  Am J Transplant       Date:  2019-12-12       Impact factor: 8.086

6.  Microbiome: an emerging new frontier in graft‑versus‑host disease.

Authors:  Reena Kumari; Senthilnathan Palaniyandi; Ethan Strattan; Gerhard C Hildebrandt
Journal:  Inflamm Res       Date:  2020-11-13       Impact factor: 4.575

Review 7.  The role of the intestinal microbiota in allogeneic HCT: clinical associations and preclinical mechanisms.

Authors:  Chi L Nguyen; Melissa D Docampo; Marcel Rm van den Brink; Kate A Markey
Journal:  Curr Opin Genet Dev       Date:  2020-12-31       Impact factor: 5.578

Review 8.  The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD).

Authors:  Christos Demosthenous; Ioanna Sakellari; Vassiliki Douka; Penelope Georgia Papayanni; Achilles Anagnostopoulos; Eleni Gavriilaki
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

Review 9.  Update in clinical and mouse microbiota research in allogeneic haematopoietic cell transplantation.

Authors:  Sarah Lindner; Jonathan U Peled
Journal:  Curr Opin Hematol       Date:  2020-11       Impact factor: 3.218

10.  The clinical role of the gut microbiome and fecal microbiota transplantation in allogeneic stem cell transplantation.

Authors:  Israel Henig; Dana Yehudai-Ofir; Tsila Zuckerman
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.